Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2024-11-26 00:00:00 ET · period of report 2024-11-22 · accession 0001415889-24-027711 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-26 | 2024-11-26 | VRCA | Rieger Jayson | CEO, Pres, Dir | G - Gift | $0.00 | +50.0K | 882.8K | +6% | $0 |
| D | 2024-11-26 | 2024-11-22 | VRCA | Rieger Jayson | CEO, Pres, Dir | P - Purchase | — | +280.9K | 832.8K | +51% | — |
| DM | 2024-11-26 | 2024-11-22 | VRCA | Rieger Jayson | CEO, Pres, Dir | P - Purchase | — | +280.9K | 140.4K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-26 | G | A | 50,000 | $0.00 | 882,826 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-22 | P | A | 280,898 | — | 832,826 | D | — | — | (F1) The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |
| 3 | Derivative | Series A Warrants (right to buy) | 2024-11-22 | P | A | 140,449 | — | 140,449 | D | $1.07 · 2024-11-22 to 2025-11-22 | 140,449 Common Stock | (F1) The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |
| 4 | Derivative | Series B Warrants (right to buy) | 2024-11-22 | P | A | 140,449 | — | 140,449 | D | $1.34 · 2024-11-22 to 2029-11-22 | 140,449 Common Stock | (F1) The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |